Groupama Asset Managment grew its holdings in Natera, Inc. (NASDAQ:NTRA – Free Report) by 19.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,256 shares of the medical research company’s stock after acquiring an additional 15,072 shares during the period. Groupama Asset Managment owned about 0.07% of Natera worth $21,135,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of NTRA. Robinhood Asset Management LLC acquired a new stake in shares of Natera in the 4th quarter worth $12,981,000. Systrade AG acquired a new stake in Natera in the fourth quarter valued at about $11,454,000. Quantbot Technologies LP acquired a new stake in Natera in the third quarter valued at about $1,069,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Natera by 5.7% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,166 shares of the medical research company’s stock valued at $25,621,000 after purchasing an additional 8,630 shares in the last quarter. Finally, J. Safra Sarasin Holding AG purchased a new stake in Natera in the 4th quarter valued at approximately $2,825,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.
Insider Activity
In other news, CFO Michael Burkes Brophy sold 3,070 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total value of $594,781.80. Following the completion of the transaction, the chief financial officer owned 58,291 shares in the company, valued at $11,293,298.34. This trade represents a 5.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares in the company, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 162,342 shares of company stock valued at $35,283,396 in the last 90 days. Insiders own 5.05% of the company’s stock.
Natera Trading Up 2.2%
Wall Street Analysts Forecast Growth
NTRA has been the subject of a number of analyst reports. Wolfe Research initiated coverage on Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price for the company. Evercore restated an “outperform” rating and issued a $270.00 price target on shares of Natera in a research note on Friday, May 8th. JPMorgan Chase & Co. upped their price objective on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Royal Bank Of Canada began coverage on Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price objective for the company. Finally, Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.53.
Get Our Latest Stock Analysis on Natera
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Recommended Stories
- Five stocks we like better than Natera
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
